DURATA THERAPEUTICS
Durata was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners. Durata is focused on Vicuronรขโฌโขs antibiotic drug candidate, dalbavancin. Its product portfolio also includes two preclinical antibiotic programs while Pfizer will retain the marketed anti-fungal agent, EraxisTM, which was formerly owned by Vicuron.
DURATA THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2009-01-01
Address:
Branford, Connecticut, United States
Country:
United States
Website Url:
http://www.duratatherapeutics.com
Total Employee:
51+
Status:
Closed
Contact:
312-219-7000
Email Addresses:
[email protected]
Total Funding:
70 M USD
Technology used in webpage:
SPF Amazon Microsoft Azure DNS Amazon Virginia Region ASP.NET Ajax Amazon Sydney Region Cisco Ironport Cloud MarkMonitor DNS Xand
Current Advisors List
P. Sherrill Neff Board of Directors @ Durata Therapeutics Board_member
James Healy Board Member @ Durata Therapeutics Board_member 2009-12-01
Current Employees Featured
Lisa Giles
Lisa Giles Independent Director @ Durata Therapeutics Independent Director
Allison Wey
Allison Wey Vice President, Investor Relations & Public Affairs @ Durata Therapeutics Vice President, Investor Relations & Public Affairs 2012-10-01
Richard U. De Schutter
Richard U. De Schutter Independent Director, Chairman of the Board @ Durata Therapeutics Independent Director, Chairman of the Board 2012-04-01
Brent Ahrens
Brent Ahrens General Partner at Canaan Partners @ Durata Therapeutics General Partner at Canaan Partners 1999-01-01
Paul A. Friedman
Paul A. Friedman Independent Director @ Durata Therapeutics Independent Director
Stock Details
Company's stock symbol is NASDAQ:DRTX
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2009-12-21 | Vicuron Pharmaceuticals | Vicuron Pharmaceuticals acquired by Durata Therapeutics | N/A |
Investors List
PDL Biopharma
PDL Biopharma investment in Post-IPO Equity - Durata Therapeutics
Official Site Inspections
http://www.duratatherapeutics.com
Unable to get host informations!!!
Loading ...